Vaibhavi Shah
Directeur Technique/Scientifique/R&D chez Inventia Healthcare Ltd.
Profil
Vaibhavi Shah is currently working as the Director of Research & Development at Inventia Healthcare Ltd.
Previously, she worked as a Research Associate at Epitomics, Inc. and GeneTech, Inc. She holds a graduate degree from the University of Iowa and an undergraduate degree from the University of Mumbai.
Postes actifs de Vaibhavi Shah
| Sociétés | Poste | Début |
|---|---|---|
Inventia Healthcare Ltd.
 Inventia Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Vaibhavi Shah
| Sociétés | Poste | Fin |
|---|---|---|
GeneTech, Inc.
 GeneTech, Inc. Medical/Nursing ServicesHealth Services GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | - |
Epitomics, Inc.
 Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Corporate Officer/Principal | - |
Formation de Vaibhavi Shah
| University of Mumbai | Undergraduate Degree |
| University of Iowa | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Inventia Healthcare Ltd.
Inventia Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India. | Health Technology |
Epitomics, Inc.
Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Health Technology |
GeneTech, Inc.
GeneTech, Inc. Medical/Nursing ServicesHealth Services GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan. | Health Services |